echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The new indication of WuXi Junuo CAR-T therapy for the treatment of follicular lymphoma is planned to be included in priority review

    The new indication of WuXi Junuo CAR-T therapy for the treatment of follicular lymphoma is planned to be included in priority review

    • Last Update: 2022-04-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 24, the CDE official website recently showed that the new indication of WuXi Junuo CAR-T therapy Ruikiorenzae injection is to be included in the priority review
    .


    The newly added indication for this application is: adult relapsed or refractory follicular lymphoma after second-line or above systemic therapy, including follicular lymphoma with histological grades 1, 2, and 3a


    It is reported that the previously approved indications are: adult patients with relapsed or refractory large B-cell lymphoma after second-line or above systemic therapy, including diffuse large B-cell lymphoma unspecified, follicular lymphoma transformed Diffuse large B-cell lymphoma, grade 3b follicular lymphoma, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangements (double hit/triple hit fight lymphoma)
    .

    Ruiji Orenxai Injection (formerly known as Ruijilunxi Injection) is an anti-CD19 CAR-T product developed by WuXi Junuo, and it is also the core candidate product of WuXi Junuo
    .


    CD19 is a specific antigen expressed on the surface of B cells


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.